Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ACTRN12625001411437) titled 'A Phase 2 Randomised Double-Blind Placebo-Controlled Trial of Topical Intranasal Botulinum Toxin Type A for the Treatment of Refractory Rhinitis' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Primary Sponsor: Metro North Hospital and Health Services
Condition:
Refractory Allergic Sinusitis
Refractory Non-Allergic Rhinitis
Refractory Allergic Sinusitis
Refractory Non-Allergic Rhinitis
Inflammatory and Immune System - Allergies
Inflammatory and Immune System - Other inflammatory or i...